Cancer stem cell targeting: The next generation of cancer therapy and molecular imaging

Therapeutic Delivery

Volumn 3, Issue 2, 2012, Pages 227-244

  Shigdar, Sarah ^a   Lin, Jia ^a   Li, Yong ^b   Yang, Chaoyong James ^c   Wei, Mingqian ^d   Zhu, Yimin ^e   Liu, Hui ^f   Duan, Wei ^a,f  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c XIAMEN UNIVERSITY   (China)

^d GRIFFITH UNIVERSITY   (Australia)

^e SUZHOU INSTITUTE OF NANO TECH AND NANO BIONICS   (China)

^f DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

A subset of the bulk cancer that gives rise to all cell types found in a particular cancer. They are responsible for initiating and maintaining the cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CATUMAXOMAB; CD133 ANTIGEN; CD33 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; HERMES ANTIGEN; IPI 926; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SONIC HEDGEHOG PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VISMODEGIB; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CARCINOMA; CELL DIFFERENTIATION; DNA DAMAGE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MEDULLOBLASTOMA; MOLECULAR IMAGING; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84863115835     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.148     Document Type: Review

References (199)

1. Klein CA. Parallel progression of primary tumors and metastases. Nat. Rev. Cancer 9, 202-212 (2009).
2. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3, 895-902 (2003). (Pubitemid 37500174)
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003). (Pubitemid 36418143)
4. Koch U, Krause M, Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures: radiation oncology perspective. Semin. Cancer Biol. 20, 116-124 (2010).
5. Shackleton M. Normal stem cells and cancer stem cells: similar and different. Semin. Cancer Biol. 20, 85-92 (2010).
6. Ebben JD, Treisman DM, Zorniak M et al. The cancer stem cell paradigm: a new understanding of tumor development and treatment. Expert Opin Ther. Targets 14, 621-632 (2010).
7. Visvader JE. Cells of origin in cancer. Nature 469, 314-322 (2011).
8. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 17, 313-319 (2011).
9. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl Cancer Inst. 98, 1777-1785 (2006). (Pubitemid 46017929)
10. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs. 1, 12-25 (2009).
11. Kvinlaug BT, Huntly BJ. Targeting cancer stem cells. Expert Opin Ther. Targets 11, 915-927 (2007). (Pubitemid 47061315)
12. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
13. O'Brien CA, Kreso A, Jamieson CHM. Cancer stem cells and self-renewal. Clin. Cancer Res. 16, 3113-3120 (2010).
14. Trumpp A, Wiestler OD. Mechanisms of disease: cancer stem cells: targeting the evil twin. Nat. Clin. Pract. Oncol. 5, 337-347 (2008). (Pubitemid 351780950)
15. Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther. 89, 491-502 (2011).
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737 (1997). (Pubitemid 27298715)
17. Liu H, Patel MR, Prescher JA et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl Acad. Sci. USA 107, 18115-18120 (2010).
18. Abraham BK, Fritz P, McClellan M et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 11, 1154-1159 (2005). (Pubitemid 40175765)
19. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007). (Pubitemid 350056407)
20. Kunju LP, Cookingham C, Toy KA et al. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod. Pathol. 24(6), 786-793 (2011).
21. Liu Q, Li JG, Zheng XY, Jin F, Dong HT. Expression of CD133, PAX2, ESA and GPR30 in invasive ductal breast carcinomas. Chin. Med. J. 122, 2763-2769 (2009).
22. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10, R25 (2008).
23. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells? J. Clin. Invest. 118, 2021-2024 (2008). (Pubitemid 351872322)
24. Todarolow M, Francipanelow MG, Medema JP, Stassilow G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138, 2151-2162 (2010).
25. Dalerba P, Dylla SJ, Park I-K et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158-10163 (2007). (Pubitemid 47175279)
26. Deng S, Yang X, Lassus H et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5, e10277 (2010).
27. Abdul Khalek FJ, Gallicano GI, Mishra L. Colon cancer stem cells. Gastrointest. Cancer Res. S16-S23 (2010).
28. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037 (2007).
29. Ischenko I, Seeliger H, Kleespies A et al. Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch. Surg. 395, 1-10 (2010).
30. Kemper K, Sprick MR, de Bree M et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 70, 719-729 (2010).
31. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat. Med. 15, 1010-1012 (2009).
32. Naka K, Hoshii T, Tadokoro Y, Hirao A. Molecular pathology of tumor-initiating cells: lessons from Philadelphia chromosome-positive leukemia. Path. Int. 61, 501-508 (2011).
33. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol. Ther. 17, 219-230 (2009).
34. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-762 (2006).
35. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829 (2009).
36. Greaves M. Cancer stem cells: back to Darwin? Semin. Cancer Biol. 20, 65-70 (2010).
37. LaBarge MA. The difficulty of targeting cancer stem cell niches. Clin. Cancer Res. 16, 3121-3129 (2010).
38. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 120, 41-50 (2010).
39. Takebe N, Ivy SP. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin. Cancer Res. 16, 3106-3112 (2010).
40. Quintana E, Shackleton M, Sabel MS et al. Efficient tumor formation by single human melanoma cells. Nature 456, 593-598 (2008).
41. Orava EW, Cicmil N, Gariepy J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim. Biophys. Acta 1798, 2190-2200 (2010).
42. Clayton S, Mousa SA. Therapeutics formulated to target cancer stem cells: is it in our future? Cancer Cell Int. 11, 7 (2011).
43. Chaffer CL, Brueckmann I, Scheel C et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108, 7950-7955 (2011).
44. Santilli G, Binda M, Zaffaroni N, Daidone MG. Breast cancer-initiating cells: insights into novel treatment strategies. Cancers 3, 1405-1425 (2011).
45. Cree IA, Glaysher S, Harvey AL. Efficacy of anticancer agents in cell lines versus human primary tumor tissue. Curr. Opin Pharmacol. 10, 375-379 (2010).
46. Baiocchi M, Biffoni M, Ricci-Vitiani L, Pilozzi E, De Maria R. New models for cancer research: human cancer stem cell xenografts. Curr. Opin Pharmacol. 10, 380-384 (2010).
47. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers and relevance. Lab. Invest. 88, 459-463 (2008). (Pubitemid 351581449)
48. Mischek D, Steinborn R, Petznek H et al. Molecularly characterised xenograft tumor mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers. J. Biomed. Biotechnol. 2009, 437284 (2009).
49. Sano D, Myers JN. Xenograft models of head and neck cancers. Head Neck Oncol. 1, 32 (2009).
50. Wang J, Miletic H, Sakariassen PO et al. A reproducible brain tumor model established from human glioblastoma biopsies. BMC Cancer 9, 465 (2009).
51. de Plater L, Lauge A, Guyader C et al. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br. J. Cancer 103, 1192-1200 (2010).
52. Steele VE, Lubet RA. The use of animal models for cancer chemoprevention drug development. Semin. Oncol. 37, 327-338 (2010).
53. Zuber J, Radtke I, Pardee TS et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23, 877-889 (2009).
54. Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin. Cancer Res. 17, 6125-6129 (2011).
55. Reddy RM, Kakarala M, Wicha MS. Clinical trial design for testing the stem cell model for the prevention and treatment of cancer. Cancers 2011, 2696-2708 (2011).
56. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol. 29, 1508-1511 (2011).
57. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
58. Fehm T, Hoffmann O, Aktas B et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 11, R59 (2009).
59. Katz RL, He W, Khanna A et al. Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study. Clin. Cancer Res. 16, 3976-3987 (2010).
60. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2003). (Pubitemid 37187480)
61. Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26, 3008-3017 (2008).
62. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumor initiating cells. Nature 432, 396-401 (2004). (Pubitemid 39551674)
63. Das S, Srikanth M, Kessler JA. Cancer stem cells and glioma. Nat. Clin. Pract. Neurol. 4, 427-435 (2008).
64. Zeppernick F, Ahmadi R, Campos B et al. Stemcell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14, 123-139 (2008).
65. Vermeulen L, Todaro M, de Sousa Mello F et al. Single-cell cloning of colon cancer stem cells reveals a multilineage differentiation capacity. Proc. Natl Acad. Sci. USA 105, 13427-13432 (2008).
66. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. Proc. Natl Acad. Sci. USA 107, 3722-3727 (2010).
67. Simeone DM. Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin. Cancer Res. 14, 5646-5648 (2008).
68. Sergeant G, Vankelecom H, Gremeaux L, Topal B. Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat. Rev. Clin. Oncol. 6, 580-586 (2009).
69. Gaviraghi M, Tunici P, Valensin S et al. Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Biosci. Rep. 31, 45-55 (2010).
70. Hermann PC, Bhaskar S, Cioffi M, Heeschen C. Cancer stem cells in solid tumors. Semin. Cancer Biol. 20, 77-84 (2010).
71. Rangwala F, Omenetti A, Diehl A. Cancer stem cells: repair gone awry? J. Oncol. doi:10.1155/2011/465343 (2011) (Epub ahead of print).
72. Neuzil J, Stantic M, Zobalova R et al. Tumor-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochem. Biophys. Res. Commun. 355, 855-859 (2007).
73. Saini V, Shoemaker RH. Potential for therapeutic targeting of tumor stem cells. Cancer Sci. 101, 16-21 (2009).
74. Frank NY, Margaryan A, Huang Y et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65, 4320-4333 (2005). (Pubitemid 40775671)
75. Wu J, Lu Y, Lee A et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10, 350-357 (2007). (Pubitemid 350065179)
76. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine 3, 761-776 (2008).
77. Lv H, He Z, Liu X et al. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs. J. Cell Biochem. 102, 75-81 (2007). (Pubitemid 47378912)
78. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer Ther. 3, 833-838 (2004). (Pubitemid 39193765)
79. Stege A, Kruhn A, Lage H. Overcoming multidrug resistance by RNA interference. Methods Mol. Biol. 596, 447-465 (2010).
80. Xia Z, Zhu Z, Zhang L et al. Specific reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells. Oncol. Rep. 20, 1433-1439 (2008).
81. Kruhn A, Wang A, Fruehauf JH, Lage H. Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells. Cell Cycle 8, 3349-3354 (2009).
82. Gewirtz AM. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J. Clin. Invest. 117, 3612-3614 (2007). (Pubitemid 350224066)
83. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31, 358-365 (2010).
84. Allan A. Cancer Stem Cells in Solid Tumors. Donnenberg VS, Zimmerlin L, Donnerberg AD (Eds). Springer, Berlin, Germany, 361-379 (2011).
85. Alama A, Orengo AM, Ferrini S, Gangemi R. Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies? Drug Discov. Today doi:10.1016/j.drudis.2011.02.005 (2011) (Epub ahead of print).
86. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 67, 8980-8984 (2007). (Pubitemid 47535877)
87. Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol. Med. 17, 103-112 (2011)
88. Fan X, Matsui W, Khaki L et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 66, 7445-7452 (2006). (Pubitemid 44289197)
89. Li T, Wen H, Brayton C et al. Moderate reduction of g-secretase attenuates amyloid burden and limits mechanism-based liabilities. J. Neurosci. 27, 10849-10859 (2007). (Pubitemid 47535873)
90. Rizzo P, Miao H, D'Souza G et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68, 5226-5235 (2008).
91. Magnifico A, Albano L, Campaner S et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 15, 2010-2021 (2009).
92. Hertweck MK, Erdfelder F, Kreuzer KA. CD44 in hematological neoplasias. Ann. Hematol. 90, 493-508 (2011).
93. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167-1174 (2006). (Pubitemid 44527352)
94. Al-Ejeh F, Smart CE, Morrison BJ et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32, 650-658 (2011).
95. Welte Y, Adjaye J, Lehrach HR, Regenbrecht CR. Cancer stem cells in solid tumors: elusive or illusive? Cell Commun. Signal. 8, 6 (2010).
96. Honeycutt KA, Roop DR. c-Myc and epidermal stem cell fate determination. J. Dermatol. 31, 368-375 (2004). (Pubitemid 38855794)
97. Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136, 1012-1024 (2009).
98. Alison MR, Islam S, Wright NA. Stem cells in cancer: instigators and propagators? J. Cell Sci. 123, 2357-2368 (2010).
99. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit. Rev. Oncol. Hematol. 40, 17-24 (2001). (Pubitemid 32923067)
100. Gires O, Bauerle PA. EpCAM as a target in cancer therapy. J. Clin. Oncol. 28, e239-e240; author reply e241-e242 (2010).
101. Winkler J, Martin-Killias P, Pluckthun A, Zangemeister-Wittke U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther. 8, 2674-2683 (2009).
102. Baumann K, Pfisterer J, Wimberger P et al. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a Phase IIa study of the AGO Study Group. Gynecol. Oncol. 123, 27-32 (2011).
103. DiMeo TA, Anderson K, Phadke P et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 69, 5364-5373 (2009).
104. Yauch RL, Gould SE, Scales SJ et al. A paracrine requirement for hedgehog signaling in cancer. Nature 455, 406-410 (2008).
105. Gao J, Graves S, Koch U et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 4, 548-558 (2009).
106. LoRusso PM, Rudin CM, Reddy JC et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 17, 2502-2511 (2011).
107. Tremblay MR, McGovern K, Read MA, Castro AC. New developments in the discovery of small molecule Hedgehog pathway antagonists. Curr. Opin Chem. Biol. 14, 428-435 (2010).
108. Strimpakos AS, Syrigos KN, Saif MW. Updates on first-line treatment of metastatic pancreatic adenocarcinoma. Presented at: The 2011 ASCO Annual Meeting. Chicago, IL, USA, 3-7 June 2011. JOP 12, 339-342 (2011).
109. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 66(4), 1883-1890 (2006).
110. Zhao C, Chen A, Jamieson CH et al. Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776-779 (2009).
111. Korkaya H, Wicha MS. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs. 21, 299-310 (2007). (Pubitemid 47529469)
112. Follo MY, Mongiorgi S, Bosi C et al. The Akt/ mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res. 67, 4287-4294 (2007). (Pubitemid 46815076)
113. Eyler CE, Foo WC, LaFiura KM et al. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 26, 3027-3036 (2008).
114. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27, 1749-1758 (2008). (Pubitemid 351380265)
115. Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 71, 634-639 (2011).
116. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol. 177, 1491-1502 (2010).
117. Soeda A, Park M, Lee D et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1a. Oncogene 28, 3949-3959 (2009).
118. Mohyeldin A, Garzon-Muvdi T, Quinones- Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 7, 150-161 (2010).
119. Bell-McGuinn KM, Matthews CM, Ho SN et al. A Phase II, single-arm study of the anti-a5b1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol. Oncol. 121, 273-279 (2011).
120. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur. J. Cancer. 46, 1323-1332 (2010).
121. Mayol JF, Loeuillet C, Herodin F, Wion D. Characterisation of normal and cancer stem cells: one experimental paradigm for two kinds of stem cells. Bioessays 31, 993-1001 (2009).
122. Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat. Rev. Mol. Cell Biol. 9, 285-296 (2008). (Pubitemid 351430845)
123. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427 (2011).
124. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82 (2007). (Pubitemid 46054518)
125. Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J. Leukoc. Biol. 89, 31-39 (2011).
126. Teicher BA, Fricker SP. CXCL12 (SDF-1)/ CXCR4 pathway in cancer. Clin. Cancer Res. 16, 2927-2931 (2010).
127. Ozpolat B, Akar U, Steiner M et al. Programmed. cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol. Cancer Res. 5, 95-108 (2007).
128. Ryningen A, Stapnes C, Lassalle P et al. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated ith the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk. Res. 33, 779-787 (2009).
129. Wiestler O, Haendler B, Mumberg D. Cancer Stem Cells. Piccirillo S, Vescovi A (Eds). Springer Berlin, Heidelberg, Germany 59-81 (2007).
130. Arce C, Perez-Plasencia C, Gonzalez-Fierro A et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 1, e98 (2006).
131. Candelaria M, Gallardo-Rincon D, Arce C et al. A Phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol. 18, 1529-1538 (2007). (Pubitemid 47365487)
132. van Rhenen A, Feller N, Kelder A et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11, 6520-6527 (2005). (Pubitemid 41338990)
133. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217-226 (2007). (Pubitemid 46143225)
134. Morel AP, Lievre M, Thomas C et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3, e2888 (2008).
135. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100, 672-679 (2008).
136. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 98, 1512-1520 (2007). (Pubitemid 47308444)
137. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mammary Gland Biol. Neoplasia 14, 29-43 (2009).
138. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008). (Pubitemid 351636299)
139. Vlashi E, Kim K, Lagadec C et al. imaging, tracking, and targeting of cancer stem cells. J. Natl Cancer Inst. 101, 350-359 (2009).
140. Hoshikawa H, Nishiyama Y, Kishino T et al. Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers. Mol. Imaging Biol. 13, 172-177 (2011).
141. Lyons SK, Brindle KM. Pre-invasive disease: Pathogenesis and Clinical Management. Fitzgerald RC (Ed.), Springer, Berlin, Germany (2011).
142. Jang YY, Ye Z, Cheng L. Molecular imaging and stem cell research. Mol. Imaging. 10, 111-122 (2011).
143. Lucignani G, Rodriguez-Porcel M. In vivo imaging for stem cell therapy: new developments and future challenges. Eur. J. Nucl. Med. Mol. Imaging 38, 400-405 (2011).
144. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8, 545-554 (2008). (Pubitemid 351881850)
145. Shapiro EM, Sharer K, Skrtic S, Koretsky AP. In vivo detection of single cells by MRI. Magn. Reson. Med. 55, 242-249 (2006). (Pubitemid 43238090)
146. Rodriguez O, Fricke S, Chien C et al. Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. Cell Cycle 5, 113-119 (2006).
147. McAteer MA, Akhtar AM, von Zur Muhlen C, Choudhury RP. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis 209, 18-27 (2010).
148. Wang K, Ruan J, Qian Q et al. BRCAA1 monoclonal antibody conjugated fluorescent magnetic nanoparticles for in vivo targeted magnetofluorescent imaging of gastric cancer. J. Nanobiotechnology 9, 23 (2011).
149. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials 32(29), 7139-7150 (2011).
150. Jacobson O, Weiss ID, Szajek LP et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics 1, 251-262 (2011).
151. Tsurumi C, Esser N, Firat E et al. Non-invasive in vivo imaging of tumor-associated CD133/prominin. PLoS One 5, e15605 (2010).
152. Jager PL, de Korte MA, Lub-de Hooge MN et al. Molecular imaging: what can be used today. Cancer Imaging 5, S27-S32 (2005).
153. Boerman OC, Oyen WJ. Immuno-PET of cancer: a revival of antibody imaging. J. Nucl. Med. 52, 1171-1172 (2011).
154. Chong G, Lee FT, Hopkins W et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin. Cancer Res. 11, 4818-4826 (2005). (Pubitemid 41568168)
155. Mankoff DA. Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res. 10(Suppl. 1), S3 (2008).
156. Romer T, Leonhardt H, Rothbauer U. Engineering antibodies and proteins for molecular in vivo imaging. Curr. Opin Biotechnol. 22(6), 882-887 (2011).
157. Baum RP, Prasad V, Muller D et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J. Nucl. Med. 51, 892-897 (2010).
158. McCarthy JR, Bhaumik J, Karver MR, Sibel Erdem S, Weissleder R. Targeted nanoagents for the detection of cancers. Mol. Oncol. 4, 511-528 (2010).
159. Cheng Z, Wu Y, Xiong Z, Gambhir SS, Chen X. Near-infrared fluorescent RGD peptides for optical imaging of integrin avb3 expression in living mice. Bioconjug. Chem. 16, 1433-1441 (2005). (Pubitemid 41681509)
160. Lee HY, Li Z, Chen K et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med. 49, 1371-1379 (2008).
161. Perkins AC, Missailidis S. Radiolabelled aptamers for tumor imaging and therapy. Q. J. Nucl. Med. Mol. Imaging 51, 292-296 (2007). (Pubitemid 350267699)
162. Kairemo K, Erba P, Bergstrom K, Pauwels EKJ. Nanoparticles in cancer. Curr. Radiopharmaceuticals 1, 30-36 (2008).
163. Farokhzad OC, Cheng J, Teply BA et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103, 6315-6320 (2006).
164. Hicke BJ, Stephens AW, Gould T et al. Tumor targeting by an aptamer. J. Nucl. Med. 47, 668-678 (2006). (Pubitemid 46768469)
165. Shigdar S, Lin J, Yu Y et al. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 102, 991-998 (2011).
166. Chen TJ, Cheng TH, Chen CY et al. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J. Biol. Inorg. Chem. 14, 253-260 (2009).
167. Kanwar JR, Roy K, Kanwar RK. Chimeric aptamers in cancer cell-targeted drug delivery. Crit. Rev. Biochem. Mol. Biol. 46(6), 459-477 (2011).
168. Bagalkot V, Zhang L, Levy-Nissenbaum E et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 7, 3065-3070 (2007).
169. Condeelis J, Weissleder R. In vivo imaging in cancer. Cold Spring Harb. Perspect Biol. 2, a003848 (2010).
170. Zou G-M. Cancer stem cells in leukemia, recent advances. J. Cell Physiol. 213, 440-444 (2007). (Pubitemid 47509725)
171. Testa U. Leukemia stem cells. Ann Hematol. 90, 245-271 (2011).
172. Hwang-Verslues WW, Kuo WH, Chang PH et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 4, e8377 (2009).
173. Ishiwata T, Matsuda Y, Naito Z. Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J. Gastroenterol. 17, 409-418 (2011).
174. Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies. J. Cell Biochem. 108, 1031-1038 (2009).
175. Tchoghandjian A, Baeza N, Colin C et al. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol. 20, 211-221 (2010).
176. Kim K-J, Lee K-H, Kim H-S et al. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology. 31(5), 494-502 (2011).
177. Mikhail S, He AR. Liver cancer stem cells. Int. J. Hepatol. 2011, 486954 (2011).
178. Rivera C, Rivera S, Loriot Y, Vozenin MC, Deutsch E. Lung cancer stem cell: new insights on experimental models and preclinical data. J. Oncol. 2011:549181 (2011) (Epub).
179. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr. Opin Biotechnol. 18, 460-466 (2007). (Pubitemid 350116595)
180. Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J. Orthop. Surg. Res. 5, 78 (2010).
181. Silva IA, Bai S, McLean K et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71, 3991-4001 (2011).
182. May R, Sureban SM, Lightfoot SA et al. Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G303-G310 (2010).
183. Griend DJV, Karthaus WL, Dalrymple S et al. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 68, 9703-9711 (2008).
184. Wei C, Guomin W, Yujun L, Ruizhe Q. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol. Ther. 6, 763-768 (2007). (Pubitemid 47328359)
185. Patrawala L, Calhoun T, Schneider-Broussard R et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25, 1696-1708 (2006).
186. Li T, Su Y, Mei Y et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab. Invest. 90, 234-244 (2010).
187. Zhang K, Waxman DJ. PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol. Cancer. 29, 319 (2010).
188. Trerotola M, Rathore S, Goel HL et al. CD133, Trop-2 and a2b1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am. J. Transl. Res. 2, 135-144 (2010).
189. Todaro M, Iovino F, Eterno V et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 70, 8874-8885 (2010).
190. Zobalova R, Prokopova K, Stantic M et al. The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection? Antioxid. Redox Signal. 15(12), 2989-3002 (2011).
191. Zhou BB, Zhang H, Damelin M et al. Tumor-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8, 806-823 (2009).
192. Maetzel D, Denzel S, Mack B et al. Nuclear signaling by tumor-associated antigen EpCAM. Nat. Cell Biol. 11, 162-171 (2009).
193. Fouladi M, Stewart CF, Olson J et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J. Clin. Oncol. 29, 3529-3534 (2011).
194. Yan M. Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc. Cell 3, 17 (2011).
195. Diaz A, Leon K. Therapeutic approaches to target cancer stem cells. Cancers 3, 3331-3352 (2011).
196. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 1, 563-577 (2010).
197. Winquist RJ, Boucher DM, Wood M, Furey BF. Targeting cancer stem cells for more effective therapies: taking out cancer's locomotive engine. Biochem. Pharmacol. 78, 326-334 (2009).
198. Cheng H, Merika E, Syrigos KN, Saif MW. Novel agents for the treatment of pancreatic adenocarcinoma. Presented at: The 2011 ASCO Annual Meeting. Chicago, IL, USA 3-7 June 2011. JOP 12, 334-338 (2011).
199. Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 29, 883-887 (2011)